$TOVX
Theriva Biologics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000141057823001584 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $212.0K $2.690M
YoY Change -92.06% 164.5%
% of Gross Profit
Research & Development $4.006M $3.133M
YoY Change 55.88% -10.1%
% of Gross Profit
Depreciation & Amortization $36.00K $30.00K
YoY Change 80.0% 66.67%
% of Gross Profit
Operating Expenses $4.218M $5.820M
YoY Change -15.88% 16.75%
Operating Profit -$4.218M -$5.820M
YoY Change -15.88% 16.75%
Interest Expense $388.0K $380.0K
YoY Change 142.5% 2135.29%
% of Operating Profit
Other Income/Expense, Net $388.0K $377.0K
YoY Change 140.99% 2117.65%
Pretax Income -$3.830M -$5.443M
YoY Change -20.62% 9.56%
Income Tax -$527.0K -$359.0K
% Of Pretax Income
Net Earnings -$3.303M -$5.100M
YoY Change -31.94% 2.66%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19 -$0.34
Diluted Earnings Per Share -$0.19 -$0.34
COMMON SHARES
Basic Shares Outstanding 17.04M 15.12M
Diluted Shares Outstanding 17.04M 15.17M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.16M $34.25M
YoY Change -38.28% -34.47%
Cash & Equivalents $31.20M $34.20M
Short-Term Investments
Other Short-Term Assets $2.032M $3.430M
YoY Change 0.1% 46.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables $176.0K $144.0K
Total Short-Term Assets $34.77M $37.97M
YoY Change -34.07% -30.83%
LONG-TERM ASSETS
Property, Plant & Equipment $389.0K $301.0K
YoY Change 48.47% 5.61%
Goodwill $5.460M $5.621M
YoY Change 28.35% 8.41%
Intangibles $18.93M $19.48M
YoY Change -5.79% -5.25%
Long-Term Investments
YoY Change
Other Assets $173.0K $120.0K
YoY Change 57.27% 0.84%
Total Long-Term Assets $26.78M $27.48M
YoY Change 3.14% 0.15%
TOTAL ASSETS
Total Short-Term Assets $34.77M $37.97M
Total Long-Term Assets $26.78M $27.48M
Total Assets $61.55M $65.45M
YoY Change -21.79% -20.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $833.0K $741.0K
YoY Change 8.18% -26.12%
Accrued Expenses $5.590M $1.826M
YoY Change 296.17% -8.1%
Deferred Revenue $525.0K
YoY Change
Short-Term Debt $65.00K $67.00K
YoY Change 25.0% 19.64%
Long-Term Debt Due $65.00K $70.00K
YoY Change 30.0% 25.0%
Total Short-Term Liabilities $8.743M $9.134M
YoY Change -33.72% -31.14%
LONG-TERM LIABILITIES
Long-Term Debt $150.0K $150.0K
YoY Change -25.0% -30.56%
Other Long-Term Liabilities $8.355M $7.460M
YoY Change 128.28% 103.16%
Total Long-Term Liabilities $8.505M $7.610M
YoY Change 120.34% 95.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.743M $9.134M
Total Long-Term Liabilities $8.505M $7.610M
Total Liabilities $17.66M $17.70M
YoY Change -14.04% -14.33%
SHAREHOLDERS EQUITY
Retained Earnings -$303.8M -$300.5M
YoY Change 6.47% 7.13%
Common Stock $346.3M $346.2M
YoY Change 0.78% 0.78%
Preferred Stock
YoY Change
Treasury Stock (at cost) $288.0K $288.0K
YoY Change
Treasury Stock Shares
Shareholders Equity $43.88M $47.75M
YoY Change
Total Liabilities & Shareholders Equity $61.55M $65.45M
YoY Change -21.79% -20.51%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$3.303M -$5.100M
YoY Change -31.94% 2.66%
Depreciation, Depletion And Amortization $36.00K $30.00K
YoY Change 80.0% 66.67%
Cash From Operating Activities -$2.955M -$3.890M
YoY Change -33.6% -10.7%
INVESTING ACTIVITIES
Capital Expenditures $126.0K $10.00K
YoY Change 530.0% -171.43%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$126.0K -$10.00K
YoY Change 530.0% -28.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.000K 2.140M
YoY Change -99.93%
NET CHANGE
Cash From Operating Activities -2.955M -3.890M
Cash From Investing Activities -126.0K -10.00K
Cash From Financing Activities 2.000K 2.140M
Net Change In Cash -3.079M -1.760M
YoY Change 77.98% -59.73%
FREE CASH FLOW
Cash From Operating Activities -$2.955M -$3.890M
Capital Expenditures $126.0K $10.00K
Free Cash Flow -$3.081M -$3.900M
YoY Change -31.07% -10.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0000894158
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
tovx Lease Rent Abatement Period1
LeaseRentAbatementPeriod1
P3M
tovx Lessee Operating Lease Short Term Agreement Term
LesseeOperatingLeaseShortTermAgreementTerm
P90D
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-12584
dei Entity Registrant Name
EntityRegistrantName
THERIVA BIOLOGICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3808303
dei Entity Address Address Line1
EntityAddressAddressLine1
9605 Medical Center Drive, Suite 270
dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
dei Entity Address Country
EntityAddressCountry
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
dei City Area Code
CityAreaCode
301
dei Local Phone Number
LocalPhoneNumber
417-4364
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TOVX
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17042765
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34248000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41786000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3717000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3734000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
37965000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
45520000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
301000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
345000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
99000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1956000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1199000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19483000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19150000
CY2023Q2 us-gaap Goodwill
Goodwill
5621000
CY2022Q4 us-gaap Goodwill
Goodwill
5525000
CY2023Q2 tovx Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2022Q4 tovx Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2023Q2 us-gaap Assets
Assets
65449000
CY2022Q4 us-gaap Assets
Assets
71861000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
741000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
915000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1826000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1496000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1070000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1403000
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4978000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
2973000
CY2023Q2 us-gaap Loans Payable Current
LoansPayableCurrent
67000
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
57000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
452000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
216000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9134000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7060000
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5773000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
7211000
CY2023Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
153000
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
221000
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
952000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1618000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1684000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1187000
CY2023Q2 us-gaap Liabilities
Liabilities
17696000
CY2022Q4 us-gaap Liabilities
Liabilities
17297000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17762010
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17041777
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15844294
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15124061
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
18000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
346176000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
343750000
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
720233
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
720233
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
288000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
288000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-356000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-679000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-300531000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-290969000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
45019000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
51830000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
65449000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71861000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2687000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1541000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4888000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3196000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3133000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3485000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6110000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6082000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
5820000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
5026000
us-gaap Operating Expenses
OperatingExpenses
10998000
us-gaap Operating Expenses
OperatingExpenses
9278000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5820000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5026000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10998000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9278000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-31000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
381000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
26000
us-gaap Investment Income Interest
InvestmentIncomeInterest
745000
us-gaap Investment Income Interest
InvestmentIncomeInterest
27000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
377000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
17000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
746000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5443000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5009000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10252000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9282000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-359000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-532000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-689000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-532000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5084000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4477000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9563000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8750000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15166209
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15166209
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15844061
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15844061
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15145252
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15145252
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14837832
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14837832
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-5084000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-4477000
us-gaap Profit Loss
ProfitLoss
-9563000
us-gaap Profit Loss
ProfitLoss
-8750000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-51000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1442000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
323000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1261000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5135000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5919000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-9240000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-10011000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
51830000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
126000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
-374000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4478000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
47852000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
146000
CY2023Q2 tovx Stock Issued During Period At Market Offering Value
StockIssuedDuringPeriodAtMarketOfferingValue
2156000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
51000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-5084000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
45019000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65408000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
112000
CY2022Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
6599000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
-181000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4273000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68027000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
113000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
1442000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-4477000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
62221000
us-gaap Profit Loss
ProfitLoss
-9563000
us-gaap Profit Loss
ProfitLoss
-8750000
us-gaap Share Based Compensation
ShareBasedCompensation
272000
us-gaap Share Based Compensation
ShareBasedCompensation
225000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-689000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-532000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
568000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-442000
tovx Non Cash Lease Expense
NonCashLeaseExpense
181000
tovx Non Cash Lease Expense
NonCashLeaseExpense
90000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
64000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
36000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-53000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-518000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-181000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-295000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
335000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
265000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-337000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-272000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-205000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-101000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9502000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9258000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000
us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
3863000
tovx Repayment Of Long Term Loans From Vendors
RepaymentOfLongTermLoansFromVendors
417000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4294000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
75000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1376000
tovx Proceeds From Issuance Of Atm Offering Net Of Issuance Costs
ProceedsFromIssuanceOfAtmOfferingNetOfIssuanceCosts
2156000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2081000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1376000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-98000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-35000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7536000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14963000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41884000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67325000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34348000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52362000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34248000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52266000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
96000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34348000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52362000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
937000
tovx Fair Value Of Contingent Consideration In Business Combination
FairValueOfContingentConsiderationInBusinessCombination
12158000
tovx Fair Value Of Equity Issued As Consideration In Business Combination
FairValueOfEquityIssuedAsConsiderationInBusinessCombination
6599000
tovx Adjustment Of Pre Close Vcn Financing
AdjustmentOfPreCloseVcnFinancing
417000
tovx Goodwill Measurement Period Adjustment
GoodwillMeasurementPeriodAdjustment
277000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34200000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7500000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-5100000
us-gaap Profit Loss
ProfitLoss
-9600000
CY2023Q2 us-gaap Cash
Cash
32800000
tovx Number Of Intangible Assets Generated As Result Of Acquisition
NumberOfIntangibleAssetsGeneratedAsResultOfAcquisition
2
tovx Long Lived Assets For Assets Property Equipment And Right Of Use Assets.
LongLivedAssetsForAssetsPropertyEquipmentAndRightOfUseAssets.
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Long-lived assets include property, equipment, and right-of-use assets. Management reviews the Company’s long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be fully recoverable. The Company determines the extent to which an asset may be impaired based upon its expectation of the asset’s future usability as well as whether there is reasonable assurance that the future cash flows associated with the asset will be in excess of its carrying amount. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and the carrying value of the asset. No impairment charges were recorded during the three and six months ended June 30, 2023 and 2022. </p>
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021Q4 us-gaap Goodwill
Goodwill
0
CY2022 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
6757000
CY2022 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-1061000
CY2022 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-171000
CY2022Q4 us-gaap Goodwill
Goodwill
5525000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
96000
CY2023Q2 us-gaap Goodwill
Goodwill
5621000
CY2023Q2 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
10971000
CY2022Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
10462000
CY2023Q2 tovx Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
2065000
CY2022Q4 tovx Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
2293000
CY2023Q2 tovx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
859000
CY2022Q4 tovx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
418000
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
321000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
637000
CY2023Q2 tovx Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
182000
CY2022Q4 tovx Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
155000
CY2023Q2 tovx Amount Receivable From Prior Owner
AmountReceivableFromPriorOwner
146000
CY2022Q4 tovx Amount Receivable From Prior Owner
AmountReceivableFromPriorOwner
144000
CY2023Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
144000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
87000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3717000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3734000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1231000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1210000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
930000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
865000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
301000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
345000
CY2023Q2 tovx Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
961000
CY2022Q4 tovx Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
807000
CY2023Q2 tovx Accrued Manufacturing Costs
AccruedManufacturingCosts
443000
CY2022Q4 tovx Accrued Manufacturing Costs
AccruedManufacturingCosts
197000
CY2023Q2 tovx Accrued Vendor Payments
AccruedVendorPayments
422000
CY2022Q4 tovx Accrued Vendor Payments
AccruedVendorPayments
492000
CY2023Q2 tovx Accrued Liabilities Current.
AccruedLiabilitiesCurrent.
1826000
CY2022Q4 tovx Accrued Liabilities Current.
AccruedLiabilitiesCurrent.
1496000
CY2023Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
606000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1216000
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
350000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
87000
CY2023Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
114000
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
100000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1070000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1403000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
673000
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.80
CY2020 tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
900000
CY2020Q4 tovx Over Allotment Option Period
OverAllotmentOptionPeriod
P45D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021Q1 tovx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
1165575
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000000.0
tovx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2022 tovx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Convertible Conversion Price Decrease
PreferredStockConvertibleConversionPriceDecrease
1.22
CY2022 tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634497
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.24
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y9M10D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
71
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
182
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634426
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.22
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y9M10D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634426
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y3M10D
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5100000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9600000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4500000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8800000
CY2022Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
8.00
CY2022Q3 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3000000.0
CY2022Q3 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
1.22
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2459016
CY2022Q3 tovx Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
20000
CY2022Q3 tovx Votes Relating To Preferred Stock
VotesRelatingToPreferredStock
1549295
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000
CY2023Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
67000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
153000
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
57000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
221000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
62000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
64000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
52000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
32000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
10000
CY2023Q2 tovx Long Term Debt.
LongTermDebt.
220000
CY2023Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P63M
CY2023Q2 tovx Percentage Of Funds To Be Borrowed By Company
PercentageOfFundsToBeBorrowedByCompany
8.5
tovx Percentage Of Office Leases Owned By Subsidiary
PercentageOfOfficeLeasesOwnedBySubsidiary
1
tovx Lessee Operating Lease Additional Renewal Term
LesseeOperatingLeaseAdditionalRenewalTerm
P5Y
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
158000
us-gaap Operating Lease Cost
OperatingLeaseCost
303000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
138000
us-gaap Operating Lease Cost
OperatingLeaseCost
245000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
327000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
664000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
674000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
589000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
367000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2621000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
485000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2136000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
452000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1684000

Files In Submission

Name View Source Status
0001410578-23-001584-index-headers.html Edgar Link pending
0001410578-23-001584-index.html Edgar Link pending
0001410578-23-001584.txt Edgar Link pending
0001410578-23-001584-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20230630.xsd Edgar Link pending
tmb-20230630x10q.htm Edgar Link pending
tmb-20230630x10q001.jpg Edgar Link pending
tmb-20230630xex31d1.htm Edgar Link pending
tmb-20230630xex32d1.htm Edgar Link pending
tmb-20230630_def.xml Edgar Link unprocessable
tmb-20230630_lab.xml Edgar Link unprocessable
tmb-20230630_pre.xml Edgar Link unprocessable
tmb-20230630x10q_htm.xml Edgar Link completed
tmb-20230630_cal.xml Edgar Link unprocessable